{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:36:11Z","timestamp":1779291371349,"version":"3.51.4"},"reference-count":9,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,5,1]]},"DOI":"10.1001\/jamadermatol.2026.0293","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:30:40Z","timestamp":1774452640000},"page":"445","source":"Crossref","is-referenced-by-count":0,"title":["Vitiligo Metrics Lack Multidimensional Severity Domains"],"prefix":"10.1001","volume":"162","author":[{"given":"Stanca A.","family":"Birlea","sequence":"first","affiliation":[{"name":"Anastasios Medical Center, Zal\u0103u, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"2","key":"ded260002r1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial.","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"ded260002r2","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jaad.2025.06.027","article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study.","volume":"93","author":"Pandya","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"ded260002r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102655","article-title":"Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study.","volume":"73","author":"Passeron","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"10244","key":"ded260002r4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"ded260002r5","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf519","article-title":"Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.","author":"Harris","journal-title":"Br J Dermatol"},{"issue":"5","key":"ded260002r6","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1111\/jocd.15637","article-title":"Recurrence and risk factors in cured patients with vitiligo: a real-life single-center retrospective study.","volume":"22","author":"Xu","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"ded260002r7","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf531","article-title":"Recurrence and relapse in non-segmental vitiligo: phenotypic and autoimmune predictors from a large retrospective cohort.","author":"Shih","journal-title":"Br J Dermatol"},{"issue":"5","key":"ded260002r8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/pcmr.12784","article-title":"Validation of a physician global assessment tool for vitiligo extent: results of an international vitiligo expert meeting.","volume":"32","author":"van Geel","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"ded260002r9","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2026.0294","article-title":"Definition of severity and relapse for vitiligo: an international consensus statement.","author":"Eleftheriadou","journal-title":"JAMA Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2846493\/jamadermatology_birlea_2026_ed_260002_1779281424.44445.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:00:24Z","timestamp":1779289224000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2846493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.0293","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}